Stocks › SLS

SELLAS Life Sciences Group, Inc.

SLS·Nasdaq·United States United States·USD
$13.66
-1.20 (-8.08%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
SLS
SELLAS Life Sciences Group, Inc. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
SLSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of SLS by members of U.S. Congress · 0 on record

No congressional trades in SLS on record.

Whale Activity

Position changes in SLS reported for 2026-09-30 by 239 institutional filers
Increased: 94New: 43Held: 31Decreased: 36Closed: 22No prior filing: 13
  • Increased94
  • New43
  • Held31
  • Decreased36
  • Closed22
  • No prior filing13
FilerSharesValueChange
BlackRock, Inc.16.2M$199.2Mincreased
STATE STREET CORP10.4M$127.7Mdecreased
VANGUARD CAPITAL MANAGEMENT LLC8.9M$110.1Mincreased
GEODE CAPITAL MANAGEMENT, LLC5.2M$63.7Mincreased
SUSQUEHANNA INTERNATIONAL GROUP, LLP2.6M$32.5Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC2.3M$28.3Mincreased
NORTHERN TRUST CORP1.9M$22.8Mincreased
CHARLES SCHWAB INVESTMENT MANAGEMENT INC1.8M$22.2Mincreased
MORGAN STANLEY1.5M$18.6Mincreased
UBS Group AG1.5M$18.3Mincreased
VANGUARD FIDUCIARY TRUST CO1.4M$17.7Mincreased
DAGCO, INC.1.3M$16.5Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by SLS insiders, by quarter · Form 4
-100.0K-50.0K050.0K100.0K2025 Q1: 02025 Q12025 Q2: 50.0K2025 Q22025 Q3: 02025 Q32025 Q4: 63.4K2025 Q42026 Q1: 02026 Q12026 Q2: 02026 Q22026 Q3: 02026 Q32026 Q4: -37.4K2026 Q4

Recent Insider Transactions

126 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Burns John ThomasCFO Sale −3,831 $19.18 $73K Nov 18, 2026 Form 4 ↗
CICIC DRAGANSVP, Chief Development Officer Sale −6,933 $19.18 $133K Nov 18, 2026 Form 4 ↗
Stergiou Angelos M.President and CEO · Director Sale −26.6K $19.18 $510K Nov 18, 2026 Form 4 ↗
Stergiou Angelos M.President and CEO · Director Grant / award +1.1M $0.00 $0 Jun 16, 2026 Form 4 ↗
Varian JohnDirector Grant / award +50.0K $0.00 $0 Jan 7, 2026 Form 4 ↗
VAN NOSTRAND ROBERT LDirector Grant / award +50.0K $0.00 $0 Jan 7, 2026 Form 4 ↗
SCHEINBERG DAVID ADirector Grant / award +50.0K $0.00 $0 Jan 7, 2026 Form 4 ↗
CICIC DRAGANSVP, Chief Development Officer Grant / award +300.0K $0.00 $0 Jan 7, 2026 Form 4 ↗
Burns John ThomasCFO Grant / award +300.0K $0.00 $0 Jan 7, 2026 Form 4 ↗
Kalin Katherine BachDirector Grant / award +50.0K $0.00 $0 Jan 7, 2026 Form 4 ↗
Wasman JaneDirector Grant / award +50.0K $0.00 $0 Jan 7, 2026 Form 4 ↗
CICIC DRAGANSVP, Chief Development Officer Other −63.8K $1.50 $96K Dec 3, 2025 Form 4 ↗
Burns John ThomasCFO Other −58.6K $1.50 $88K Dec 3, 2025 Form 4 ↗
Stergiou Angelos M.President and CEO · Director Other −187.1K $1.50 $281K Dec 3, 2025 Form 4 ↗
Kalin Katherine BachDirector Purchase +63.4K $1.59 $101K Nov 19, 2025 Form 4 ↗
VAN NOSTRAND ROBERT LDirector Purchase +10.0K $1.48 $15K Jun 12, 2025 Form 4 ↗
Wasman JaneDirector Purchase +20.0K $1.69 $34K May 30, 2025 Form 4 ↗
Kalin Katherine BachDirector Purchase +20.0K $1.80 $36K May 22, 2025 Form 4 ↗
Burns John ThomasCFO Grant / award +81.3K $0.00 $0 Jan 10, 2025 Form 4 ↗
Burns John ThomasCFO Grant / award +113.0K $0.00 $0 Jan 10, 2025 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding SLS · SEC Form N-PORT
FundSharesValue% of fundAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
8.7M$127.7M1.19%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
5.9M$87.2M0.00%Jun 30, 2026
iShares Russell 2000 ETF
iShares Trust
4.9M$72.7M0.09%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
2.1M$31.5M0.03%Jun 30, 2026
iShares Russell 2000 Growth ETF
iShares Trust
1.7M$25.7M0.17%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
2.1M$20.7M0.06%Jul 31, 2026
VANGUARD RUSSELL 2000 INDEX FUND
VANGUARD SCOTTSDALE FUNDS
1.1M$14.4M0.08%Aug 31, 2026
Fidelity Extended Market Index Fund
Fidelity Concord Street Trust
910.7K$12.1M0.03%Aug 31, 2026
iShares Micro-Cap ETF
iShares Trust
632.2K$9.3M0.61%Jun 30, 2026
VANGUARD HEALTH CARE INDEX FUND
VANGUARD WORLD FUND
546.8K$7.3M0.03%Aug 31, 2026

Mutual funds and ETFs whose N-PORT filings list SLS's shares (CUSIP 81642T209), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 10.4M shares5.1%
    Nov 10, 2026 · ↗
  • BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 15.9M shares7.9%
    Oct 27, 2026 · ↗
  • STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 13.0M shares7.0%
    Aug 7, 2026 · ↗
  • Vanguard Capital ManagementSCHEDULE 13G · passive (13G) · 9.7M shares5.2%
    Jul 31, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming SELLAS Life Sciences Group, Inc. as client

No lobbying filings found naming SELLAS Life Sciences Group, Inc. as the client.

Government Contracts

Federal awards to SELLAS Life Sciences Group, Inc. · USAspending

No federal contract awards found for SELLAS Life Sciences Group, Inc..

U.S. Patents

Recent USPTO applications naming SELLAS Life Sciences Group, Inc.

No USPTO patent applications found for SELLAS Life Sciences Group, Inc..

Annual Financials

From SLS's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenuen/an/a$0$1.0M$7.6M
Operating income-$28.3M-$31.5M-$37.9M-$42.0M-$25.3M
Net income-$26.9M-$30.9M-$37.3M-$41.3M-$20.7M
Diluted EPS-$0.25-$0.50-$1.34-$2.13-$1.34
Operating cash flow-$28.4M-$35.4M-$31.4M-$23.8M-$26.0M
Cash and equivalents$71.8M$13.9M$2.5M$17.1M$21.4M
Total assets$78.3M$19.4M$6.2M$20.9M$26.3M
Total liabilities$7.5M$10.0M$14.2M$16.1M$5.9M
Shareholders' equity$70.9M$9.5M-$8.0M$4.9M$20.3M

As SELLAS Life Sciences Group, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 19, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-50Reverse splitNov 8, 2019
  • 1-for-30Reverse splitJan 2, 2018

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 1.01, 8.01, 9.01Material agreement · Other eventsNov 20, 2026
    EDGAR ↗
  • 8-K · Items 7.01, 8.01, 9.01Reg FD disclosure · Other eventsNov 17, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsNov 12, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 11, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 8.01, 9.01Results of operations · Other eventsJul 27, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 9.01Officer / director changeJun 25, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteJun 18, 2026
    EDGAR ↗
  • 8-K · Items 8.01, 9.01Other eventsJun 2, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 12, 2026
    EDGAR ↗

About SELLAS Life Sciences Group, Inc.

From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersNEW YORK, NY
IncorporatedDE
Former namesGALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP